News

Press Releases

Jul 14, 2004

Mylan's Levothyroxine Sodium Tablets Approved as a Generic Equivalent to Levoxyl®
Jul 2, 2004

Mylan Enters Into a Settlement and License Agreement Ending Paclitaxel Litigation
Jul 1, 2004

Mylan's NDA for Nebivolol Accepted for FDA Review
Jun 30, 2004

Mylan Submits a Supplement to Its Citizens Petition Regarding Authorized Generics to the FDA
Jun 29, 2004

Mylan Names Margaret McKenna Chief Business Development Officer
Jun 28, 2004

Mylan Nominates Rod Piatt to its Board of Directors
Jun 25, 2004

Mylan Receives $37.5 Million and Settles All Outstanding Disputes With Schwarz Pharma's KUDCo and Related Parties
Jun 24, 2004

Mylan Receives FDA Approval for Levothyroxine Sodium Tablets
Jun 23, 2004

Mylan Sues FDA for Injunction Against Fentanyl Ruling
Jun 22, 2004

Mylan Laboratories Appoints Michael Marquard President of Mylan Bertek Pharmaceuticals
Jun 17, 2004

Mylan Declares Quarterly Cash Dividend
Jun 15, 2004

Mylan Announces Name Change for its Branded Products Subsidiary to Mylan Bertek
Jun 10, 2004

Mylan Receives FDA Approval for Ciprofloxacin Tablets
May 11, 2004

Mylan Reports Record EPS, Revenues and Net Earnings for Fiscal 2004

Annual Financial Highlights: * Record diluted earnings per share of $1.21 compared to $0.96 in the prior fiscal year. * Net revenues increased 8% to a record $1.37 billion. * Net earnings increased 23% to a record $334.6 million.
May 6, 2004

Mylan Receives Tentative Approval for Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended-release Tablets
May 5, 2004

Mylan Submits New Drug Application for Nebivolol
Apr 29, 2004

Mylan Announces Earnings Release Date and Conference Call Information for Fourth Quarter and Fiscal 2004

Show per page

Mylan: Seeing is Believing

You are leaving Mylan.com

By clicking Continue below you are leaving Mylan.com and going to a third-party site.

Continue

Go back